"Navigating the Modern News Zoo so you don't have to."
Tuesday, September 16, 2025
Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity
A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual care, diet and exercise, and weight loss surgeries.
đ Full Story
Five Quality Stocks To Buy Now
- DAVE BOSSIE: GOP Canât Afford A Disaster In Louisiana Senate Race - David Bossie
- The Hidden Expenses to Owning a Boat
- Elon Musk's Ambitious Plan: To Send One Million Humans to Mars within the Next Decade - Michael A. Medeiros
- Two men fell gravely ill last year; their infections link to deaths in the â80s - Beth Mole
- The Evolution and Impact of Internet Jokes: A Closer Look at Prank.Chat - Bertha Stephens
- The Full Moons of 2024: A Comprehensive Guide to Their Names and Dates - Arya Chandran
The ATF Might Be Evolving - This is NOT Good
- The Folly of Tucker Carlsonâs Neo-Feudalism - Hunter Oswald
- The GOP Shouldnât Give Up the Obamacare Fight (Again) - Jack Butler
- We Asked Dietitians How to Make Fall Drinks HealthierâHereâs What They Recommend Ordering - Christina Manian, RDN
- In the Trump v Wind Wars, Ărsted Now 'Battling' for Survival
- iOS 18 Elevates the iPhone with Unmatched Personalization and Intelligence - Michael A. Medeiros
- Star Trekâs Biggest Star Might Just Save the Franchise - Chris Snellgrove
